Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/142513
Full metadata record
DC FieldValueLanguage
dc.creatorCampos, C
dc.creatorFragoso, S
dc.creatorLuís, R
dc.creatorPinto, F
dc.creatorBrito, C
dc.creatorEsteves, S
dc.creatorPataco, M
dc.creatorSantos, S
dc.creatorMachado, P
dc.creatorVicente, JB
dc.creatorRosa, JC
dc.creatorCavaco, BM
dc.creatorMoura, C
dc.creatorPojo, M
dc.date.accessioned2022-08-01T11:22:01Z-
dc.date.available2022-08-01T11:22:01Z-
dc.date.issued2020
dc.identifier.issn2073-4425
dc.identifier.urihttps://hdl.handle.net/10216/142513-
dc.description.abstractCutaneous melanoma is one of the most aggressive human cancers due to its high invasiveness. Germline mutations in high-risk melanoma susceptibility genes have been associated with development hereditary melanoma; however, most genetic culprits remain elusive. To unravel novel susceptibility genes for hereditary melanoma, we performed whole exome sequencing (WES) on eight patients with multiple primary melanomas, high number of nevi, and negative for high and intermediate-risk germline mutations. Thirteen new potentially pathogenic variants were identified after bioinformatics analysis and validation. CDH23, ARHGEF40, and BRD9 were identified as the most promising susceptibility genes in hereditary melanoma. In silico analysis of CDH23 and ARHGEF40 variants provided clues for altered protein structure and function associated with the identified mutations. Then, we also evaluated the clinical value of CDH23, ARHGEF40, and BRD9 expression in sporadic melanoma by using the TCGA dataset (n = 461). No differences were observed in BRD9 expression between melanoma and normal skin samples, nor with melanoma stage, whereas ARHGEF40 was found overexpressed, and CDH23 was downregulated and its loss was associated with worse survival. Altogether, these results reveal three novel genes with clinical relevance in hereditary and sporadic melanoma.
dc.description.sponsorshipThe authors are thankful for the collaboration of all departments involved from IPOLFG, Lisboa, Portugal. F.P. received a grant from National Funds through the Foundation for Science and Technology (FCT), reference SFRH/BPD/115730/2016. The authors are thankful for the financial support to Liga Portuguesa Contra o Cancro, Núcleo Regional Sul (LPCC-NRS), IPOLFG, TVI (Televisão Independente) and iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344), co-funded by FCT/Ministério da Ciência e do Ensino Superior, through national funds, and FEDER under the PT2020 Partnership Agreement.
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_NORTE/SFRH%2FBPD%2F115730%2F2016/PT
dc.relation.ispartofGenes, vol.11(4):403
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshCadherin Related Proteins
dc.subject.meshCadherins / genetics
dc.subject.meshExome / genetics
dc.subject.meshFemale
dc.subject.meshGene Expression Regulation, Neoplastic / genetics
dc.subject.meshGenetic Predisposition to Disease
dc.subject.meshGerm-Line Mutation / genetics
dc.subject.meshGuanine Nucleotide Exchange Factors / genetics
dc.subject.meshHigh-Throughput Nucleotide Sequencing / methods
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMelanoma / genetics
dc.subject.meshMelanoma / pathology
dc.subject.meshMiddle Aged
dc.subject.meshTranscription Factors / genetics
dc.subject.meshWhole Exome Sequencing / methods
dc.titleHigh-throughput sequencing identifies 3 novel susceptibility genes for hereditary melanoma
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/genes11040403
dc.relation.publisherversionhttps://www.mdpi.com/2073-4425/11/4/403
Appears in Collections:ICBAS - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-genes11040403.pdf2.87 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons